At this week’s ACS meeting in New Orleans, Fimbrion Therapeutics Inc. presented the rational design of a different series of small-molecule biaryl O- and C-linked mannoside-based inhibitors of the virulence factor FimH, as potential agents for the treatment of urinary tract infections (UTIs).
Shanghai Allist Pharmaceuticals Co. Ltd. has patented nitrogen-containing heterocyclic compounds acting as GTPase KRAS, particularly G12D or G12V mutant, inhibitors reported to be useful for the treatment of cancer.
Work at Hangzhou Highlightll Pharmaceutical Co. Ltd. has led to the development of tyrosine-protein kinase JAK1, JAK2 and non-receptor tyrosine-protein kinase TYK2 inhibitors.
Abbvie Inc. has prepared and tested new antibody-drug conjugates comprising an antibody targeting seizure protein 6 homolog (SEZ6) covalently linked to DNA topoisomerase I inhibitors through a linker.
Asgard Therapeutics AB has raised €30 million (US$32.8 million) in a series A round to advance a novel approach to cancer immunotherapy, in which it is proposed to reprogram cancer cells into functional antigen-presenting dendritic cells in vivo, activating a host immune response against the tumor.
Cytokinetics Inc. has disclosed fast skeletal muscle myosin inhibitors reported to be useful for the treatment of Becker muscular dystrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, spinal cord injury, limb girdle muscular dystrophy, stroke, tendinitis and tremor, among others.
Jawaharlal Nehru Centre for Advanced Scientific Research has divulged naphthalene monoimide compounds acting as modulators of liquid-liquid phase separation (LLPS) of tau protein reported to be useful for the treatment of traumatic encephalopathy, progressive supranuclear palsy, tauopathies, frontotemporal dementia and Alzheimer’s disease.
RSS
